Natco Pharma posts over two-fold jump in Q2 PAT to ₹ 181.6 crore
Natco Pharma reported over two-fold increase in consolidated profit after tax at ₹ 181.6 crore for the second quarter ended September 30, 2018. The company had posted a consolidated profit after tax of ₹ 84.4 crore in the same quarter last fiscal, Natco Pharma said in a regulatory filing.
Total revenue during the period under review stood at ₹ 583.5 crore. It was at ₹ 432.2 crore in the year-ago quarter. The company said its board of directors at its meeting on Monday had approved the buyback of fully paid-up equity shares of face value of ₹ 2 each at a price not exceeding ₹ 1,000 per share for an aggregate amount of ₹ 2,50 crore from the open market through stock exchange mechanism. The maximum buyback size represents 8.10 per cent and 8.22 per cent of the aggregate of the total paid up equity capital and free reserves, respectively, of the company, it added.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Best Service Pharmaceutical Producer CAS 2381089-83-2 Retatrutide 5mg Weight Loss Peptide
$70/MT FOB
2026-07-04
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Fuhrmann Hanlin Reports Strong Performance in the First Three Quarters of 2023
-
Chinese pharmaceutical companies enter overseas to record with up to $5 billion in licensing fees!
-
Roche's TIGIT Monoclonal Antibody Collapses Again, And A Large Number of Domestic Biopharmaceutical Companies are Deployed
-
Yantai Development Zone builds an integrated industrial chain of pharmaceutical R&D and manufacturing to promote the industrialization of new biological drugs
-
Why Chinese biopharmaceutical companies building factories to expand production
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
Recommend Reading
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Recent Formic Acid Market Shows "Decreased Volume, Stable Prices" Trend in China
-
Evonik Launches Asia’s First Alkoxide Plant in Jurong Island
-
Costs Decline, DOP Prices Retreat from High Levels This Week
-
Costs Drop Significantly, Prices of 2-Ethylhexanol Fall in China
-
Loose Supply, Weak and Declining Aniline Market (Dec. 8–Dec. 12)